Closely held PharmaJet announced it will present insights from several DNA cancer vaccine partner trials using PharmaJet’s Precision Delivery Systems at the World Vaccine Congress (WVC) on April 23, 2025 at 12:25 pm ET.
According to PharmaJet, the presentation, titled What if Delivery Is the Missing Link in Cancer Immunotherapy? Insights from DNA Cancer Vaccine Trials Using Needle-Free Injection Delivery, will share data demonstrating that PharmaJet technology can induce robust T cell responses and tumor or lesion reduction in difficult-to-treat cancer populations. Several partner vaccine trials will be discussed including specific DNA cancer vaccines administered with the PharmaJet systems. PharmaJet will also be delivering a pre-conference presentation titled Navigating the Immune System starts with Precise Delivery, during the Vaccine Delivery Session on April 21, 2025, from 2:00 – 5:00 PM in Room 202A.
In a statement, Nathalie Landry, CSO of PharmaJet, commented, “We are proud to support our oncology partners in their development of cancer vaccines and therapeutics with our needle-free delivery systems. Our body of data highlights how our needle-free technology can be expected to enhance vaccine immune response, and how it contributes to inducing T cell-mediated immune responses in difficult-to-treat cancer populations. We are encouraged by these results and the potential for needle-free delivery to further enhance various lines of cancer vaccines and therapies.”
